Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

MRI in Evaluating Early Response to Chemotherapy in Women Receiving Chemotherapy for Infiltrating Breast Cancer

This study has been completed.
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: April 18, 2007
Last updated: May 12, 2011
Last verified: December 2008

RATIONALE: Diagnostic procedures, such as magnetic resonance imaging (MRI), may help in learning how well chemotherapy works to kill breast cancer cells and allow doctors to plan better treatment. Drugs used in chemotherapy, such as epirubicin and docetaxel, may stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.

PURPOSE: This clinical trial is studying MRI in evaluating early response to chemotherapy in women receiving chemotherapy for infiltrating breast cancer.

Condition Intervention
Breast Cancer
Drug: docetaxel
Drug: epirubicin hydrochloride
Procedure: conventional surgery
Procedure: dynamic contrast-enhanced magnetic resonance imaging
Procedure: neoadjuvant therapy
Procedure: radiomammography

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Primary Purpose: Diagnostic
Official Title: Study Evaluating the Contribution of MRI for the Evaluation of Early Response to Neoadjuvant Chemotherapy in Patients With Infiltrative Breast Cancer

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Reproducibility and repeatability of MRI

Secondary Outcome Measures:
  • Results of MRI vs mammogram
  • MRI accuracy

Estimated Enrollment: 30
Study Start Date: February 2006
Primary Completion Date: May 2011 (Final data collection date for primary outcome measure)
Detailed Description:



  • Evaluate the feasibility (reproducibility and repeatability) of MRI for assessing tumor vascularity in women receiving neoadjuvant chemotherapy for infiltrative breast cancer.


  • Compare the results obtained by semiquantitative measurement of vascularization (MRI) vs traditional empirical evaluation.
  • Evaluate the MRI accuracy for the measurement of tumoral volume after completion of chemotherapy.

OUTLINE: This is an uncontrolled, nonrandomized study.

Patients receive neoadjuvant chemotherapy comprising epirubicin hydrochloride IV and docetaxel IV on day 1. Treatment repeats every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity.

Patients undergo dynamic-contrast MRI before treatment, 3 weeks after the first course of chemotherapy, and 3 weeks after the completion of chemotherapy. They also undergo a bilateral mammogram and sonography and clinical examination.

Within 22-35 days after completion of chemotherapy, patients undergo breast-conserving surgical resection of tumor and lymph nodes or mastectomy.

PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No


  • Histologically confirmed infiltrative breast cancer meeting 1 of the following criteria:

    • Operable T2 or T3, M0 disease
    • Locally advanced disease (T4a, b, or c)

      • No T4d disease
  • Indication for neoadjuvant chemotherapy before breast-conserving surgery

    • No desire by patient for complete mastectomy
  • No overexpression of HER-2
  • No multifocal tumor
  • Hormone receptor status not specified


  • Female
  • Menopausal status not specified
  • Life expectancy > 6 months
  • No contraindication to MRI with contrast, including any of the following:

    • Claustrophobia
    • Prior major allergies
    • Cardiac pacemaker
    • Surgical clips
    • Certain cardiac valves
    • Sunken or hollow filters
    • Implanted pump
    • Cochlear implants
    • Metallic foreign body (intra-ocular)
  • No contraindication to chemotherapy or surgery
  • No other serious condition that would preclude study therapy
  • No other uncontrolled medical condition, including any of the following:

    • Thyroid disease
    • Neuropsychiatric disease
    • Infection
    • Insufficient coronary capacity
    • NYHA class III-IV heart disease
  • No HIV positivity
  • Not pregnant or nursing


  • See Disease Characteristics
  • No prior chemotherapy, radiotherapy, or surgery for ipsilateral breast cancer
  • No prior biopsy of tumor before MRI
  • No MRI at another center within the past 15 days
  • No participation in another investigational study of anticancer therapy within the past 30 days
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00462696

Institut Bergonie
Bordeaux, France, 33076
Sponsors and Collaborators
Institut Bergonié
Study Chair: Fabienne Valentin, MD Institut Bergonié
  More Information Identifier: NCT00462696     History of Changes
Other Study ID Numbers: CDR0000540537
Study First Received: April 18, 2007
Last Updated: May 12, 2011

Keywords provided by National Cancer Institute (NCI):
stage II breast cancer
stage IIIA breast cancer
stage IIIB breast cancer
stage IIIC breast cancer

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Antibiotics, Antineoplastic
Antineoplastic Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on April 28, 2017